EA201790796A8 - НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ - Google Patents

НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ

Info

Publication number
EA201790796A8
EA201790796A8 EA201790796A EA201790796A EA201790796A8 EA 201790796 A8 EA201790796 A8 EA 201790796A8 EA 201790796 A EA201790796 A EA 201790796A EA 201790796 A EA201790796 A EA 201790796A EA 201790796 A8 EA201790796 A8 EA 201790796A8
Authority
EA
Eurasian Patent Office
Prior art keywords
thieno
benzo
derivative
digidro
azepin
Prior art date
Application number
EA201790796A
Other languages
English (en)
Russian (ru)
Other versions
EA201790796A1 (ru
Inventor
Саймон Фрейзер Хант
Стюарт Томас Онионз
Владимир Шербухин
Юэн Александер Фрейзер Фордайс
Питер Джон Мюррей
Дэниел Уильям Брукс
Кадзухиро Ито
Питер Стронг
Мэттью Стивен Коутс
Original Assignee
Палмосайд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Палмосайд Лимитед filed Critical Палмосайд Лимитед
Publication of EA201790796A1 publication Critical patent/EA201790796A1/ru
Publication of EA201790796A8 publication Critical patent/EA201790796A8/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201790796A 2014-10-10 2015-10-08 НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ EA201790796A8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188494 2014-10-10
PCT/GB2015/052944 WO2016055791A1 (en) 2014-10-10 2015-10-08 Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative

Publications (2)

Publication Number Publication Date
EA201790796A1 EA201790796A1 (ru) 2017-09-29
EA201790796A8 true EA201790796A8 (ru) 2018-10-31

Family

ID=51842340

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790796A EA201790796A8 (ru) 2014-10-10 2015-10-08 НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ

Country Status (13)

Country Link
US (6) US10189863B2 (2)
EP (2) EP3204388B1 (2)
JP (2) JP2017531039A (2)
KR (1) KR20170058921A (2)
CN (1) CN106852144B (2)
AU (1) AU2015329789B2 (2)
BR (1) BR112017005104B1 (2)
CA (1) CA2957868C (2)
EA (1) EA201790796A8 (2)
IL (1) IL250823A0 (2)
MX (1) MX2017004652A (2)
SG (1) SG11201701184WA (2)
WO (2) WO2016055792A1 (2)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531039A (ja) 2014-10-10 2017-10-19 プルモシデ リミテド 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体
JP6694886B2 (ja) 2014-12-18 2020-05-20 プルモシデ リミテド 4,5−ジヒドロ−6H−チエノ[3,2−d]ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス(RSV)感染を治療するためのその使用
DK3324977T3 (da) 2015-07-22 2022-10-17 Enanta Pharm Inc Benzodiazepinderivater som rsv-inhibitorer
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EP3411028B1 (en) 2016-02-03 2021-05-05 Janssen Sciences Ireland Unlimited Company Combination product for treating or ameliorating respiratory syncytial virus infection
WO2017175000A1 (en) * 2016-04-08 2017-10-12 Pulmocide Limited Compounds
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006291A1 (en) * 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
WO2019199908A1 (en) * 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
WO2020210246A1 (en) * 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
AU2020357452B2 (en) 2019-10-04 2026-01-29 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) * 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2022182861A1 (en) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693635A (en) 1993-07-29 1997-12-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
US20110052643A1 (en) * 2008-01-07 2011-03-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2011005842A1 (en) 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
PE20130774A1 (es) 2010-07-29 2013-06-26 Rigel Pharmaceuticals Inc Compuestos heterociclicos activadores de ampk y metodos para emplearlos
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
PE20170673A1 (es) 2014-08-05 2017-05-22 Alios Biopharma Inc Terapia de combinacion para tratar una paramixovirus
JP2017531039A (ja) 2014-10-10 2017-10-19 プルモシデ リミテド 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EP3411028B1 (en) 2016-02-03 2021-05-05 Janssen Sciences Ireland Unlimited Company Combination product for treating or ameliorating respiratory syncytial virus infection
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS

Also Published As

Publication number Publication date
EP3204389B1 (en) 2019-06-26
CN106852144B (zh) 2019-08-30
EA201790796A1 (ru) 2017-09-29
US20170305935A1 (en) 2017-10-26
JP2017531038A (ja) 2017-10-19
US20170190718A1 (en) 2017-07-06
EP3204389A1 (en) 2017-08-16
SG11201701184WA (en) 2017-03-30
US10035810B2 (en) 2018-07-31
WO2016055792A1 (en) 2016-04-14
JP6675407B2 (ja) 2020-04-01
EP3204388B1 (en) 2018-12-12
US9926335B2 (en) 2018-03-27
CA2957868A1 (en) 2016-04-14
US20170355717A1 (en) 2017-12-14
US10273249B2 (en) 2019-04-30
JP2017531039A (ja) 2017-10-19
US10189863B2 (en) 2019-01-29
BR112017005104B1 (pt) 2022-08-23
CN106852144A (zh) 2017-06-13
AU2015329789A1 (en) 2017-03-09
US10472375B2 (en) 2019-11-12
KR20170058921A (ko) 2017-05-29
AU2015329789B2 (en) 2019-09-26
EP3204388A1 (en) 2017-08-16
US20180319820A1 (en) 2018-11-08
IL250823A0 (en) 2017-04-30
WO2016055791A1 (en) 2016-04-14
US20190202841A1 (en) 2019-07-04
BR112017005104A2 (pt) 2017-12-05
MX2017004652A (es) 2017-06-19
US9732098B2 (en) 2017-08-15
CA2957868C (en) 2023-02-28
US20180179228A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
EA201790796A1 (ru) НОВОЕ 5,6-ДИГИДРО-4H-БЕНЗО[b]ТИЕНО-[2,3-d]АЗЕПИНОВОЕ ПРОИЗВОДНОЕ
SG11201704512PA (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
UA118759C2 (uk) Сполуки 3,4-дигідроізохінолін-2(1н)-ілу
PL3174870T3 (pl) Tieno[3,2-d]pirymidyny, furo[3,2-d]pirymidyny i pirolo[3,2- d]pirymidyny przydatne do leczenia zakażeń syncytialnym wirusem oddechowym
MA52906A (fr) Procédé de préparation d'amg 416
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
EA201992832A1 (ru) Подкожное введение adamts13
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
EP3312951A4 (en) SPARK PLUG
EP3373402A4 (en) SPARK PLUG
EP3389154A4 (en) SPARK PLUG
EP3346559A4 (en) Spark plug
CY1121709T1 (el) Παραγωγο τετραϋδροπυρρολο[3,4-d][1,3]θειαζινης ως αναστολεας της bace
EP3312954A4 (en) SPARK PLUG
AU2015221431A8 (en) Novel 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds
UA115756C2 (uk) ЗАСТОСУВАННЯ 3-АРИЛАМІНОМЕТИЛ-6,7,8,9-ТЕТРАГІДРО-5H-[1,2,4]ТРИАЗОЛО[4,3-а]АЗЕПІНІВ ЯК АНАЛЬГЕТИКІВ
PL3630093T3 (pl) LECZENIE CHORÓB ZWIĄZANYCH Z NIEPRAWIDŁOWYM FUNKCJONOWANIEM SZLAKU mTOR
UA99983U (ru) 2-амино-4-метил-7-оксо-9-фенил-3-циано-6,7,8,9-тетрагидропиридо[3',2'4,5]тиено[3,2-b]пиридин
RU2014115449A (ru) N-карбэтоксиметилимидазо[4,5-e]бензо[1,2-c;3,4-c']дифуроксан
TH1601002954A (th) ออกตะไฮโดร-ไซโคลบิวตะ[1,2-c;3,4-c']ไดไพร์โรล-2-อิล ใหม่
UA85864U (en) 2-cycloalkylamino-5-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl]-5h-7-phenyl[1,3]thiazolo[4,5-d]pyridazine -4-ones exhibiting antioxidant properties
UA111273C2 (uk) Ліофілізований препарат для ін'єкцій
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом